Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
Haematologica
.
2022 Jan 1;107(1):284-286.
doi: 10.3324/haematol.2021.278772.
Authors
Urvi A Shah
1
,
Sæmundur Rögnvaldsson
2
,
Andriy Derkach
3
,
Magnus Björkholm
4
,
Ingemar Turesson
5
,
Yael David
6
,
Malin Hultcrantz
7
,
Carlyn Tan
7
,
Hani Hassoun
7
,
Neha Korde
7
,
Alexander Lesokhin
7
,
Sham Mailankody
7
,
Sigurður Yngvi Kristinsson
8
,
C Ola Landgren
9
Affiliations
1
Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York.
[email protected]
.
2
Department of Medicine, University of Iceland.
3
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York.
4
Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm.
5
Department of Hematology, Skane University Hospital Malmö/Lund.
6
Department of Chemical Biology, Sloan Kettering Institute, New York.
7
Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York.
8
Department of Medicine, University of Iceland, Iceland; Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm.
9
Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami.
PMID:
34474548
PMCID:
PMC8719074
DOI:
10.3324/haematol.2021.278772
No abstract available
Publication types
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
MeSH terms
Diabetes Mellitus*
Humans
Lymphoproliferative Disorders* / diagnosis
Lymphoproliferative Disorders* / etiology
Plasma Cells
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States
R25 CA203650/CA/NCI NIH HHS/United States
R35 GM138386/GM/NIGMS NIH HHS/United States